thymocyte selection associated family member 2Genealiases: C1orf38 · ICB-1 · ICB1
Q-omics provides the consensus-scored THEMIS2 profile across patient tissues and cancer cell-line models. THEMIS2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, THEMIS2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, THEMIS2 protein abundance shows 40,475 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where THEMIS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THEMIS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THEMIS2 survival associations across molecular data types. THEMIS2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THEMIS2 RNA expression–survival associations across cancer types. High THEMIS2 expression shows unfavorable associations in UVM, OV, LGG and LAML, but favorable associations in HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for THEMIS2 RNA expression.
This table summarizes THEMIS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for THEMIS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THEMIS2 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, HNSC, KIRP and THCA. The KIRC box plot shows higher THEMIS2 RNA expression in tumor versus normal tissue (log2 FC = +2.145, t-test p < 0.001).
This table shows molecular features associated with THEMIS2 in patient tissues and cancer cell lines. In patient samples, THEMIS2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, THEMIS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
